© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
3828 SCHAUFELE AVE
May 15, 2013
Remarkably, within 2 years of the introduction of ipilimumab and vemurafenib into the clinic, major new advances have been reported in both the immune checkpoint blockade and small-molecule kinase inhibition arenas.